EGeen Contact Clients Locations Team EGeen Therapeutic areas Services
5 May, 2021 08:46 CET
EGeen International Completes Clinical Trial Recruitment Ahead of Schedule.
MOUNTAIN VIEW, CA – Following successful clinical trial approvals, EGeen International, Inc., working in close collaboration with Retrotope, Inc., the study sponsor, completed the patient enrolment in the multicenter Phase 2 clinical trial evaluating RT001 in patients with amyotrophic lateral sclerosis in ahead of schedule:
Amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) is a rare yet devastating disease with no current effective treatment options. RT001 is an isotopically stabilized, synthetic linoleic acid developed by Retrotope to down-regulate lipid peroxidation, a hallmark of many neurodegenerative diseases including ALS.

EGeen International, Inc. is known for its rapid, cost-effective IntelligenTrials ® clinical trial management platform geared towards agile biopharmaceutical companies.

For more information, please visit Retrotope is clinical-stage biopharmaceutical company focused on the development of first-in class therapies for degenerative diseases ranging from orphan neurodegenerative indications to large market degenerative conditions. The company leverages its proprietary drug discovery platform to create novel, disease-modifying drugs designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It does so through the creation of isotopically stabilized synthetic versions of polyunsaturated fatty acids (PUFAs) that trigger the downregulation of the LPO process. The company’s lead development candidate, RT001, is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) that is in development for a range of orphan neurodegenerative diseases, including infantile neuroaxonal dystrophy (INAD), Friedreich’s ataxia (FA), amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and progressive supranuclear palsy (PSP). In addition, the company is advancing its second development candidate, RT011, an isotopically stabilized, synthetic docosahexaenoic acid (DHA), toward the clinic for the treatment of dry age-related macular degeneration (AMD).

For more information, please visit
E-Mail: 1949 Landings Drive Mountain View, CA 94043 Copyright © EGeen Inc. 2022